Xintela AB
1XT
Company Profile
Business description
Xintela AB is a clinical-stage biopharmaceutical company that develops cutting-edge medical products in stem cell therapy and targeted cancer therapy. Its wholly owned subsidiary, Targinta AB, develops First-in-Class therapeutic antibodies targeting integrin α10β1. TARG9, an antibody-drug conjugate (ADC), and TARG10, a function-blocking antibody, are in preclinical development for the treatment of aggressive, difficult-to-treat cancers, including triple-negative breast cancer and brain tumor glioblastoma. Xintela has two clinical studies ongoing with the stem cell product XSTEM and EQSTEM.
Contact
Medicon Village
Lund223 81
SWET: +46 462756500
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
11
Stocks News & Analysis
stocks
The best AI stocks to buy now
Artificial intelligence stocks maintain their allure, thanks to industry momentum and appealing valuations.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,877.70 | 54.50 | 0.62% |
| CAC 40 | 7,803.33 | 73.64 | 0.95% |
| DAX 40 | 25,087.27 | 280.30 | 1.13% |
| Dow JONES (US) | 51,654.95 | 423.31 | 0.83% |
| FTSE 100 | 10,552.05 | 110.45 | 1.06% |
| HKSE | 24,211.35 | 425.56 | 1.79% |
| NASDAQ | 27,366.17 | 172.83 | 0.64% |
| Nikkei 225 | 69,030.92 | 11.19 | -0.02% |
| NZX 50 Index | 13,749.35 | 57.50 | 0.42% |
| S&P 500 | 7,811.54 | 46.18 | 0.59% |
| S&P/ASX 200 | 8,716.60 | 55.70 | 0.64% |
| SSE Composite Index | 3,813.79 | 1.89 | 0.05% |